可溶性 CD40 配体激活的人外周 B 细胞作为替代抗原提呈细胞：抗 HBV 免疫治疗的初步方法。

Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy.

机构信息

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, PR China.

出版信息

Virol J. 2010 Dec 23;7:370. doi: 10.1186/1743-422X-7-370.

BACKGROUND

We aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes (CTLs).

RESULTS

Human B cells could be cultured in the presence of sCD40L up to 54 days, and the proportion of B cells in the S phase increased from 0% to 8.34% in the culture. The expression of CD80, CD86, major histocompatibility complex (MHC) classes I and II molecules on the sCD40L-activated B cell was significantly increased after long-time culture. Cytometry and fluorescence microscopy showed that more than 98% sCD40L-activated B cells were loaded by the HBcAg peptide. Furthermore, the peptide-pulsed activated B cells could induce HBcAg18-27 specific CTLs.

CONCLUSIONS

Our results demonstrate that sCD40L-activated B cells may function as APCs and induce HBV-specific CTLs.

背景

我们旨在阐明可溶性 CD40 配体 (sCD40L) 是否可以激活 B 细胞并负载 HBcAg18-27 肽，作为产生抗原的细胞 (APCs) 来诱导乙型肝炎病毒特异性细胞毒性 T 淋巴细胞 (CTLs)。

结果

人 B 细胞可在 sCD40L 的存在下培养长达 54 天，培养物中 B 细胞 S 期的比例从 0%增加到 8.34%。sCD40L 激活的 B 细胞上 CD80、CD86、主要组织相容性复合体 (MHC) Ⅰ类和Ⅱ类分子的表达在长时间培养后显著增加。流式细胞术和荧光显微镜显示，超过 98%的 sCD40L 激活的 B 细胞被 HBcAg 肽负载。此外，肽脉冲激活的 B 细胞可以诱导 HBcAg18-27 特异性 CTLs。